Organometallic pyridocarbazole scaffolds are investigated as protein kinase inhibitors. Whereas our previous designs employed solely a maleimide pharmacophore for achieving the two crucial canonical hydrogen bonds to the hinge region of the ATP binding site, we have now extended our investigations to include the related lactam metallo-pyridocarbazoles. The synthetic access of the two regioisomeric lactam pyridocarbazoles is described and the distinct biological properties of the two lactam scaffolds are revealed by employing a ruthenium half sandwich complex as a model system, resulting in organometallic lead structures for the inhibition of the protein kinases TrkA and CLK2. These new lactam metallo-pyridocarbazoles expand our existing molecular toolbox and assist towards the generation of metal complex scaffolds as lead structures for the design of selective inhibitors for numerous kinases of the human kinome.meggers@chemie.uni-marburg.de. Supporting Information Available: Screening results of compounds 1-3 and (R Ru )-21 against a panel of human kinases, assignment of the absolute configurations of (R Ru )-1, (S Ru )-1, (R Ru )-2, (S Ru )-2, (R Ru )-21, 1 H-1 H-ROESY analysis of compound 17, and NMR spectra for all new compounds. This material is available free of charge via the Internet at